Advertisement

Molecular Medicine

, Volume 19, Issue 1, pp 409–416 | Cite as

Iodine Uptake and Prostate Cancer in the TRAMP Mouse Model

  • Paloma Olvera-Caltzontzin
  • Guadalupe Delgado
  • Carmen Aceves
  • Brenda Anguiano
Research Article

Abstract

Iodine supplementation exerts antitumor effects in several types of cancer. Iodide (I) and Iodine (I2) reduce cell proliferation and induce apoptosis in human prostate cancer cells (LNCaP and DU-145). Both chemical species decrease tumor growth in athymic mice xenografted with DU-145 cells. The aim of this study was to analyze the uptake and effects of iodine in a preclinical model of prostate cancer (transgenic adenocarcinoma of the mouse prostate [TRAMP] mice/SV40-TAG antigens), which develops cancer by 12 wks of age. 125I and 125I2 uptake was analyzed in prostates from wild-type and TRAMP mice of 12 and 24 wks in the presence of perchlorate (inhibitor of the Na+/I symporter [NIS]). NIS expression was quantified by quantitative polymerase chain reaction (qPCR). Mice (6 wks old) were supplemented with 0.125 mg I plus 0.062 mg I2/mouse/day for 12 or 24 wks. The weight of the genitourinary tract (GUT), the number of acini with lesions, cell proliferation (levels of proliferating cell nuclear antigen [PCNA] by immunohistochemistry), p53 and p21 expression (by qPCR) and apoptosis (relative amount of nucleosomes by enzyme-linked immunosorbent assay) were evaluated. In both age-groups, normal and tumoral prostates take up both forms of iodine, but only I uptake was blocked by perchlorate. Iodine supplementation prevented the overexpression of NIS in the TRAMP mice, but had no effect on the GUT weight, cell phenotype, proliferation or apoptosis. In TRAMP mice, iodine increased p53 expression but had no effect on p21 (a p53-dependent gene). Our data corroborate NIS involvement in I uptake and support the notion that another transporter mediates I2 uptake. Iodine did not prevent cancer progression. This result could be explained by a strong inactivation of the p53 pathway by TAG antigens.

Notes

Acknowledgments

This study was supported by grants from Programa de Apoyo a Proyectos de Investigación e Inovación Tecnológica. Universidad Nacional Autónoma de México (PAPIIT-UNAM; IN202513, IN200813) and Consejo Nacional de Ciencia y Tecnología (CONACYT; 127368, 176911). P Olvera-Caltzontzin was a graduate student of the Programa de Doctorado en Ciencias Biomédicas, UNAM, and received a scholarship from CONACYT (215709). The authors thank Martín García, Alejandra Castilla, and Moisés Pérez-Mendoza for technical assistance; Francisco Valles, Leonor Casanova and Lourdes Lara for academic support; Ramon Martínez, Alberto Lara and Omar González for computer assistance; and Dr. Dorothy Pless for proofreading.

References

  1. 1.
    Ferlay J, et al. (2010) GLOBOCAN 2008 v2.0, cancer incidence and mortality worldwide: IARC Cancer-Base no. 10 [Internet]. Lyon (France): International Agency for Research on Cancer; [cited 2013 Dec 4]. Available from: https://doi.org/globocan.iarc.fr.Google Scholar
  2. 2.
    Sonoda T, et al. (1997) A case-control study of diet and prostate cancer in Japan: possible protective effect of traditional Japanese diet. Cancer Sci. 95:238–42.CrossRefGoogle Scholar
  3. 3.
    Key TJ, Silcocks PB, Davey GK, Appleby PN, Bishop DT. (1997) A case-control study of diet and prostate cancer. Br. J. Cancer. 76:678–87.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Hoption Cann SA, Qiu Z, van Netten C. (2007) A prospective study of iodine status, thyroid function, and prostate cancer risk: follow-up of the First National Health and Nutrition Examination Survey. Nutr. Cancer. 58:28–34.CrossRefPubMedGoogle Scholar
  5. 5.
    Aceves C, Anguiano B, Delgado G. (2013) The extrathyronine actions of iodine: antioxidant, apoptotic and differentiator factor in iodine-uptake tissues. Thyroid. 23:938–46.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Bizhanova A, Kopp P. (2009) Minireview: the sodium-iodide symporter NIS and pendrin in iodide homeostasis of the thyroid. Endocrinology. 150:1084–90.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Küpper FC, et al. (1998) Iodine uptake in laminariales involves extracellular, haloperoxidasemediated oxidation of iodide. Planta. 207:163–71.CrossRefGoogle Scholar
  8. 8.
    Arroyo-Helguera O, Anguiano B, Delgado G, Aceves C. (2006) Uptake and antiproliferative effect of molecular iodine in the MCF-7 breast cancer cell line. Endocr. Relat. Cancer. 13:1147–58.CrossRefPubMedGoogle Scholar
  9. 9.
    Rösner H, Torremante P, Möller W, Gärtner R. (2010) Antiproliferative/cytotoxic activity of molecular iodine and iodolactones in various human carcinoma cell lines: no interfering with EGF-signaling, but evidence for apoptosis. Exp. Clin. Endocrinol. Diabetes. 8:410–9.Google Scholar
  10. 10.
    Liu XH, Chen GG, Vlantis AC, Tse GM, van Hasselt CA. (2010) Iodine induces apoptosis via regulating MAPKs-related p53, p21, and Bcl-xL in thyroid cancer cells. Mol. Cell. Endocrinol. 320:128–35.CrossRefPubMedGoogle Scholar
  11. 11.
    Shrivastava A, et al. (2006) Molecular iodine induces caspase-independent apoptosis in human breast carcinoma cells involving the mitochondriamediated pathway. J. Biol. Chem. 281:19762–71.CrossRefPubMedGoogle Scholar
  12. 12.
    Arroyo-Helguera O, Rojas E, Delgado G, Aceves C. (2008) Signaling pathways involved in the antiproliferative effect of molecular iodine in normal and tumoral breast cells: evidence that 6-iodolactone mediates apoptotic effects. Endocr. Relat. Cancer. 15:1003–11.CrossRefPubMedGoogle Scholar
  13. 13.
    Aceves C, et al. (2009) Antineoplastic effect of iodine in mammary cancer: participation of 6-iodolactone (6-IL) and peroxisome proliferator-activated receptors (PPAR). Mol. Cancer. 8:33–41.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Mendieta I, Nunez-Anita E, Delgado G, Aceves C. (2011) Differential effect of iodine on the implantation and metastatic potential of xenografts from two different human breast cancer cell lines [abstract]. Cancer Res. 71(8 Suppl):Abstract nr 4224.Google Scholar
  15. 15.
    Huang M, et al. (2001) Ectopic expression of the thyroperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer. Cancer Gene Ther. 8:612–8.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Soriano O, et al. (2011) Antineoplastic effect of iodine and iodide in dimethylbenz[a]anthracene-induced mammary tumors: association between lactoperoxidase and estrogen-adduct production. Endocr. Relat. Cancer. 18:529–39.CrossRefPubMedGoogle Scholar
  17. 17.
    Vitale M, et al. (2000) Iodide excess induces apoptosis in thyroid cells through a p53-independent mechanism involving oxidative stress. Endocrinology. 141:598–605.CrossRefPubMedGoogle Scholar
  18. 18.
    Langer R, Burzler C, Bechtner G, Gärtner R. (2003) Influence of iodide and iodolactones on thyroid apoptosis: evidence that apoptosis induced by iodide is mediated by iodolactones in intact porcine thyroid follicles. Exp. Clin. Endocrinol. Diabetes. 111:325–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Thomasz L, et al. (2010) 6 Iodo-delta-lactone reproduces many but not all the effects of iodide. Mol. Cell. Endocrinol. 323:161–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Nuñez-Anita RE, Arroyo-Helguera O, Cajero-Juárez M, López-Bojorquez L, Aceves C. (2009) A complex between 6-iodolactone and the peroxisome proliferator-activated receptor type gamma may mediate the antineoplastic effect of iodine in mammary cancer. Prostaglandins Other Lipid Mediat. 89:34–42.CrossRefPubMedGoogle Scholar
  21. 21.
    Spitzweg C, Joba W, Eisenmenger W, Heufelder AE. (1998) Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary deoxyribonucleic acids from salivary gland, mammary gland, and gastric mucosa. J. Clin. Endocrinol. Metab. 83:1746–51.CrossRefPubMedGoogle Scholar
  22. 22.
    Lacroix L, et al. (2001) Na(+)/I(−) symporter and Pendred syndrome gene and protein expressions in human extra-thyroidal tissues. Eur. J. Endocrinol. 144:297–302.CrossRefPubMedGoogle Scholar
  23. 23.
    Perron B, Rodriguez AM, Leblanc G, Pourcher T. (2001) Cloning of the mouse sodium iodide symporter and its expression in the mammary gland and other tissues. J. Endocrinol. 170:185–96.CrossRefPubMedGoogle Scholar
  24. 24.
    Navarra M, et al. (2010) Expression of the sodium/iodide symporter in human prostate adenocarcinoma. Urology. 75:773–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Aranda N, Sosa S, Delgado G, Aceves C, Anguiano B. (2013) Uptake and antitumoral effects of iodine and 6-iodolactone in differentiated and undifferentiated human prostate cancer cell lines. Prostate. 73:31–41.CrossRefPubMedGoogle Scholar
  26. 26.
    (2001 Aug 22) Norma Oficial Mexicana NOM-062-ZOO-1999, Especificaciones técnicas para la producción, cuidado y uso de los animales de laboratorio. Mexico City: Diario Oficial de la Federación; [cited 2013 Dec 4]. Available from: https://doi.org/www.senasica.gob.mx/?doc=743.
  27. 27.
    McAlpine RK. (1945) The rate of oxidation of iodide ion by hydrogen peroxide. J. Chem. Educ. 22:387–90.CrossRefGoogle Scholar
  28. 28.
    York RG, et al. (2005) Refining the effects observed in a developmental neurobehavioral study of ammonium perchlorate administered orally in drinking water to rats. I. Thyroid and reproductive effects. Int. J. Toxicol. 24:403–18.CrossRefPubMedGoogle Scholar
  29. 29.
    Kaplan-Lefko PJ, et al. (2003) Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate. 55:219–37.CrossRefPubMedGoogle Scholar
  30. 30.
    Anguiano B, García-Solís P, Delgado G, Aceves Velasco C. (2007) Uptake and gene expression with antitumoral doses of iodine in thyroid and mammary gland: evidence that chronic administration has no harmful effects. Thyroid. 17:851–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Dohán O, Baloch Z, Bánrévi Z, Livolsi V, Carrasco N. (2001) Rapid communication: predominant intracellular overexpression of the Na(+)/I(−) symporter (NIS) in a large sampling of thyroid cancer cases. J. Clin. Endocrinol. Metab. 86:2697–700.PubMedGoogle Scholar
  32. 32.
    Wapnir IL, et al. (2003) Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J. Clin. Endocrinol. Metab. 88:1880–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Wapnir IL, et al. (2004) The Na+/I− symporter mediates iodide uptake in breast cancer metastases and can be selectively down-regulated in the thyroid. Clin. Cancer Res. 10:4294–302.CrossRefPubMedGoogle Scholar
  34. 34.
    Kollecker I, et al. (2012) Subcellular distribution of the sodium iodide symporter in benign and malignant thyroid tissues. Thyroid. 22:529–35.CrossRefPubMedGoogle Scholar
  35. 35.
    Miller AE, Heyland A. (2013) Iodine accumulation in sea urchin larvae is dependent on peroxide. J. Exp. Biol. 216:915–26.CrossRefPubMedGoogle Scholar
  36. 36.
    Aceves C, Anguiano B. (2009) Is Iodine an Antioxidant and Antiproliferative Agent for the Mammary and Prostate Glands? In: Comprehensive Handbook of Iodine: Nutritional, Endocrine and Pathological Aspects. Preedy VR, Burrow GN, Watson RR (eds.) London, Academic Press (Elsevier), pp. 249–57.CrossRefGoogle Scholar
  37. 37.
    Nguewa PA, Calvo A. (2010) Use of transgenic mice as models for prostate cancer chemoprevention. Curr. Mol. Med. 10:705–18.CrossRefPubMedGoogle Scholar
  38. 38.
    Gupta S, et al. (2004) Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res. 64:3334–43.CrossRefPubMedGoogle Scholar
  39. 39.
    Narayanan BA, Narayanan NK, Pittman B, Reddy BS. (2004) Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin. Cancer Res. 10:7727–37.CrossRefPubMedGoogle Scholar
  40. 40.
    Bonorden MJ, et al. (2012) Growth and progression of TRAMP prostate tumors in relationship to diet and obesity. Prostate Cancer. 2012:543970.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Berman-Booty LD, et al. (2013) Suppression of prostate epithelial proliferation and intraprostatic progrowth signaling in transgenic mice by a new energy restriction-mimetic agent. Cancer Prev. Res. (Phila). 6:232–41.CrossRefGoogle Scholar
  42. 42.
    Huss WJ, et al. (2007) Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model. Neoplasia. 9:938–50.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Chiaverotti T, et al. (2008) Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am. J. Pathol. 172:236–46.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Godoy-García L, Nava-Villalba M, Delgado G, Aceves C. (2013) Molecular iodine adjuvancy in the antineoplastic effect of retinoic acid on neuroblastoma cells [abstract]. Eur. J. Cancer. 49 Suppl 2:S363.Google Scholar

Copyright information

© The Author(s) 2013

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (https://doi.org/creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  • Paloma Olvera-Caltzontzin
    • 1
  • Guadalupe Delgado
    • 1
  • Carmen Aceves
    • 1
  • Brenda Anguiano
    • 1
  1. 1.Departamento de Neurobiología Celular y Molecular, Instituto de NeurobiologíaUniversidad Nacional Autónoma de MéxicoQuerétaroMéxico

Personalised recommendations